Capricor Therapeutics (CAPR) Tops Q3 EPS by 1c

Capricor Therapeutics (NASDAQ: CAPR) reported Q3 EPS of ($0.26), $0.01 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $1.59 million versus the consensus estimate of $420 thousand.

For earnings history and earnings-related data on Capricor Therapeutics (CAPR) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• BNP Paribas Exane Downgrades Lanxess AG (LXS:GR) (LNXSF) to Underperform
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance